Rebecca Edelmayer

Potential clinical meaningfulness of donanemab data

A call to review the CMS national coverage determination of anti-amyloid antibodies

ALZ-NET: examining novel approved treatments in the real-world

Topline donanemab results: most positive Phase III data to date